To determine whether BETi treatment may contribute to improved therapeutic outcomes in BRAF-mutant melanoma in vivo, we compared the triple combination of BRAFi/MEKi/BETi with BRAF/MEK targeting in xenograft models (Supplementary Fig. 6A). The gene discussed is MAP2K7; the disease is melanoma.